Factors Modifying Response to Breast Cancer Treatment

Dear Colleagues,

This Special Issue will provide an opportunity for investigators to participate in a collaborative effort.  Individual authors will benefit individually from combined interest in the accumulated information. Each author will reap a benefit from the fact that topics of particular interest will bring together readers that otherwise would not see related work that is published individually. Treatment differences based on histopathologic classification, tumor grade, staging (tumor size, lymph node involvement, and distant metastases), biomarker/receptor status, and molecular/genomic subtypes will be explored. The specific responses and limitations of drugs that promote DNA damage, inhibit checkpoint responses, promote retinoid responses, and inhibit PARP1 will be cosidered. Issues regarding the interactions of steroids and their receptors with drugs that limit, or in some cases improve, the response to therapy will be investigated.  This Special Issue will draw the attention of practicing physicians and investigators by presenting several concomitant perspectives in one place.

The purpose of this Special Issue is to present the new insights into “Factors affecting breast cancer treatment responses.”

We welcome reviews as well as original research articles, which should be submitted by 5 December 2026.

You may choose our Joint Special Issue in Cancers.

Dr. Robert Treat Treat Chatterton
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathophysiology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.